Radiopharm Theranostics Limited (RADX)
| Market Cap | 36.76M -0.4% |
| Revenue (ttm) | 10.86M +4,823.5% |
| Net Income | -31.07M |
| EPS | -0.01 |
| Shares Out | 3.54B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,075 |
| Open | 2.900 |
| Previous Close | 2.790 |
| Day's Range | 2.715 - 2.925 |
| 52-Week Range | 2.620 - 16.250 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 17.15 (+512.5%) |
| Earnings Date | Aug 28, 2026 |
About RADX
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $17.15, which is an increase of 512.50% from the latest price.
News
Radiopharm Theranostics (RADX) Secures $4.1M in Direct Offering
Radiopharm Theranostics (RADX) Secures $4.1M in Direct Offering
Radiopharm announces $4.1M registered direct offering
Radiopharm (RADX) announced that it has entered into a securities purchase agreement, or SPA, with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1.282M Ame...
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on de...
Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204
(RTTNews) - Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced two key clinical updates today from its pipeline pro...
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminar...
Radiopharm Reports Positive Phase 2b Data For RAD101 In Brain Metastases Diagnosis
(RTTNews) - Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company, on Wednesday reported positive data from the Phase 2b trial of RAD101 in participants with suspected recurr...
Radiopharm Theranostics trading halted, news pending
19:56 EDT Radiopharm (RADX) Theranostics trading halted, news pending
Radiopharm initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Radiopharm (RADX) with a Buy rating and $6 price target The company seeks to expand the cancer patient populations that may benefit from targeted radiotherapy,…
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference
A differentiated radiopharmaceutical pipeline is advancing four clinical programs in parallel, with near-term catalysts expected from ongoing phase I and II trials. Imaging agent RAD 101 is nearing phase III and potential commercialization, while operational efficiency and strategic partnerships support growth.
Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference
Radiopharm Theranostics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t...
Radiopharm Theranostics Earnings release: Q3 2026
Radiopharm Theranostics released its Q3 2026 earnings on April 22, 2026, summarizing the period's financial results.
Radiopharm announces new data from Phase 0/1 HEAT trial
Radiopharm (RADX) Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as ...
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
Radiopharm (RADX) announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the nex...
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2566.66% surge in interes...
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinica...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2,318.18% surge in intere...
Radiopharm Theranostics Transcript: Study result
Interim phase II-B results for RAD101 in brain metastases show 90% of patients achieving the primary endpoint, with PET imaging providing clear diagnostic value over MRI, especially in equivocal cases. The study is nearing completion, with phase III preparations underway and strong commercial interest reported.
Radiopharm Theranostics Press release: Study result
Radiopharm Theranostics issued a press release on March 24, 2026, disclosing material business information to investors.
Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference
RAD101 phase II-B interim results showed strong efficacy in brain metastasis, with final data due by mid-year and phase III planning underway. Multiple first-in-class clinical programs are advancing, with key readouts for RAD204 and RAD202 expected by year-end.
Radiopharm doses first patient in Phase 1/2a study of BetaBart
Radiopharm (RADX) Theranostics announced the dosing of the first patient in its First-In-Human, FIH, Phase 1/2a clinical trial of 177Lu-Betabart. The Phase 1/2a clinical trial is a dose escalation and...
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases
Radiopharm Theranostics Earnings release: Q2 2026
Radiopharm Theranostics released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.